[In vitro effect of rosoxacin on hospital bacteria. Results of a multicenter study].
This work reports a multicenter study of antibacterial activity of rosoxacin, a new antibacterial agent of the quinolone group. Enterobacteriaceae are very sensitive to rosoxacin (modal MIC 0,5 micrograms/ml); resistant strains are observed in all species, but more often among Serratia and Citrobacter. Pseudomonas aeruginosa is less sensitive with a maximum number of strains between 2 and 8 micrograms/ml, so it is nearly for Acinetobacter. Haemophilus are very sensitive, having MIC of 0,03 and 0,06 micrograms/ml. The spectrum of rosoxacin includes Gram positive bacteria, since the MIC of Staphylococci are similar to Enterobacteriaceae; Enterococci are less sensitive, the major part of the strains being inhibited by 4 and 8 micrograms/ml.
D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D005602:France; D006761:Hospitals; D006801:Humans; D008826:Microbial Sensitivity Tests; D011804:Quinolines / Q000494:pharmacology*; D015363:Quinolones
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D011804:Quinolines; D015363:Quinolones; C021083:rosoxacin
Activité in vitro de la rosoxacine sur les bactéries hospitalières. Résultats d'une étude multicentrique.